Z24 Bio converges biology, medicine, engineering, artificial intelligence, and quantum computing to create an ethical, efficient, and precise human-centric platform for drug testing.
Z24 Bio develops an AI-integrated, 3D-bioprinted human-tissue platform enabling pharmaceuticals to predict toxicity earlier, de-risk pipelines, cut costs and time, reduce animal use, and avoid late-stage attrition.
Scientific Publications
In partnership with
FDA NAMs-Aligned
Predictive Toxicology
AI-Driven Analytics
Human-Centric Models
Digital Organ Twins
Quantum-Enhanced Modeling
Patented Technology
Precision Disease Models
Reduced Animal Testing
FDA NAMs-Aligned
Predictive Toxicology
AI-Driven Analytics
Human-Centric Models
Digital Organ Twins
Quantum-Enhanced Modeling
Patented Technology
Precision Disease Models
Reduced Animal Testing
Z24 Bio converges biology, medicine, engineering, artificial intelligence, and quantum computing to create an ethical, efficient, and precise human-centric platform for drug testing.
Developing a new drug typically takes 12–15 years and costs $2–3 billion. Yet, nearly 90% of candidates fail after animal testing due to poor human relevance. The drug industry urgently needs ethical, scalable, human-centric models to accelerate discovery and reduce risk.
Most candidates that pass animal studies do not translate to humans.
Drug development is extremely slow and expensive. Drug industry need faster, cheaper ways to prioritize leads and de-risk INDs.
Animal and 2D in-vitro models often miss human-specific toxicity and efficacy signals.
Regulatory agencies are encouraging New Approach Methods (NAMs) and there is strong ethical impetus to reduce animal testing.
Pharma requires reproducible, high-throughput human tissue assays that integrate with existing R&D workflows and regulatory needs.
We create high-fidelity human tissues by integrating 3D bioprinting, organ-on-chip microfluidics, advanced biomaterials, AI-driven analytics and modeling. This enables us to predict drug safety and efficacy with unmatched accuracy, reducing time, cost, and reliance on animal testing.
High-fidelity human liver, heart, and other organs for predictive drug screening.
Deeper pattern recognition, enabling faster, more accurate and personalized predictions.
We deliver next-generation drug discovery services that replace outdated animal models with scalable, ethical, and predictive human tissue platforms. We integrate 3D bioprinting, organ-on-chip systems, AI analytics, and quantum modeling to help pharma de-risk pipelines and accelerate approvals.
Miniaturized human liver, heart, and other organ models for high-throughput screening.
Scalable drug testing to predict efficacy and toxicity with greater human relevance.
Tailor-made organoid and body-on-chip systems aligned with client pipelines and indications.
Advanced algorithms reveal deep insights into drug safety, efficacy, and patient-specific responses.
Our patented innovative human-centric platform transforms how drugs are tested, delivering accurate predictions earlier, reducing costs, and fast-tracking approvals. Here’s how we give our customers the edge:
Reduce the 90% failure rate of animal models with tissue platforms that mimic real human biology.
High-throughput tissue plates enable rapid, reproducible assays that plug into existing R&D pipelines, shortening timelines, lowering per-assay cost, and accelerating go/no-go decisions.
Unlock deeper analytics and patient-specific predictions, driving precision medicine and regulatory acceptance.
Accelerated by the startAD HealthX (Department of Health - Abu Dhabi) to validate our platform and pilot opportunities with regional partners.
Participating in Antler × Mubadala’s national program — recognition for our commercial potential and access to elite founder networks and investors.
On the occasion of Emirati Women’s day, our founder and CEO, Dr.Soja Soman talked about how women leaders can be the torch bearers of the technology innovations in the region.
